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Dear Editor:
It is surprising that the authors in their letter totally disregarded the main message of our investigation (Tamborini et al, 2002) . Focusing on a single case (case 18), where the genotype did not completely fit with the morphology, through very peculiar speculations, they reached the conclusion that the difference between the "experimental" results obtained by us and other groups and their own (O'Sullivan et al, 2000) , lies on the "interpretation."
We disagree with the authors' conclusion, which is in keeping with the final statement of their reply letter published in the July issue of Modern Pathology: "We would render the diagnosis of MPNST for a malignant spindle cell tumor arising in a nerve in a patient with NF1. . .even if the tumor were shown to harbor t(X;18)" (O'Sullivan et al, 2001) .
Our investigation, prompted by their unexpected demonstration of t(X;18) in 15 (75%) of 20 of MPNSTs (Tamborini et al, 2002) , clearly showed that MPNSTs do not share this translocation with SS and that the 2 (5.1%) of 34 cases that carried this hallmark were both miscategorized SSs, one of which had unusual MPNST-featuring morphology.
We purposely disregard the authors' provocative comments on our case material, which we consider suitable to verify the authors' results, being mainly made up of clinically, morphologically, and molecularly selected MPNSTs (Tamborini et al, 2002) , of which more than one half were represented by NF1 cases. Otherwise, our results are confirmed by 141 additional cases analyzed by karyotyping or RT-PCR on frozen material in five different laboratories around the world (Landani et al, 2001 ).
Finally, we would like to spend some words about the "lively debate" regarding the "uncommon" occurrence of cases with "discordant morphology and molecular findings" and about which of the two features "more accurately predict patient outcome." Concerning the inconsistency between morphology and genotyping, in our experience and in the quoted literature, this phenomenon involves untreated and post-treated tumors and raises diagnostic problems that may be successfully overcome through the integration of both morphologic and molecular analyses (Barr et al, 1995; Knezevich et al, 1998; Maeda et al, 1998; Mezzelani et al, 1998; Naguera et al, 1998; Thorner et al, 1996) . As to the outcome, recent preliminary findings in untreated sarcomas suggest that the disease outcome is driven by the genotyping rather than by morphology (Folpe and Weiss, 2002; Pilotti et al, 2000) . Moreover, according to current understanding, genotype and morphologic phenotype both are powerful determinants for a tailored tumor management and thus outcome prediction. Similar to breast and head and neck carcinomas, primary chemotherapy started to be introduced into sarcoma-treatment schemes. In treated cases the disease outcome may be significantly modified according to the drug disease sensitivity. Besides few specific tumor-targeting treatments, such as STI 571 in GISTs, the schemes applied are conventional chemotherapy based. In line with recently published data (Johnstone et al, 2002) , knowledge about tumor gene profile, in addition to drug mechanism of action, will become determinant for choosing effective treatments. However, this emerging role of genotype will not withdraw any power to the morphology that remains the milestone for categorization and natural history prediction of diseases.
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